Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Watson has reached a settlement with Novartis on outstanding patent litigation related to its generic version of Alzheimer's disease treatment Exelon capsules.
Subscribe to our email newsletter
Under the terms of the settlement agreement, Novartis has granted Watson a license to its US patents covering Exelon for a generic version of the drug. The agreement generally provides that Watson will not commence marketing its generic equivalent product until sometime prior to the expiration of the patents covering Exelon.
The specific date on which Watson may launch its generic product and other details concerning the settlement have not been disclosed.
Watson’s abbreviated new drug application for its generic version of Exelon has been tentatively approved by the FDA.